Research programme: glucagon receptor antagonists - Merck
Latest Information Update: 04 Nov 2017
At a glance
- Originator Merck & Co
- Class Imidazoles; Indazoles; Indoles
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 23 Aug 2012 Preclinical development is ongoing in USA
- 05 Apr 2011 Preclinical development is ongoing in USA